- Home
- FE vs WST Comparison
FE vs WST Comparison
Compare FE & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | WST |
|---|---|---|
| Founded | 1996 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1B | 25.6B |
| IPO Year | 2005 | 2004 |
Fundamental Metrics
Financial Performance| Metric | FE | WST |
|---|---|---|
| Price | $49.54 | $356.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $51.46 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 3.0M | 682.9K |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.80% | 0.30% |
| EPS Growth | ★ 3.53 | 1.49 |
| EPS | 0.70 | ★ 4.07 |
| Revenue | ★ $15,090,000,000.00 | $2,886,900,000.00 |
| Revenue This Year | $4.34 | $6.76 |
| Revenue Next Year | $3.98 | $6.22 |
| P/E Ratio | ★ $70.69 | $185.05 |
| Revenue Growth | ★ 12.01 | 1.95 |
| 52 Week Low | $41.30 | $223.83 |
| 52 Week High | $52.34 | $386.00 |
Technical Indicators
Market Signals| Indicator | FE | WST |
|---|---|---|
| Relative Strength Index (RSI) | 58.88 | 69.10 |
| Support Level | $48.22 | $349.41 |
| Resistance Level | $52.01 | N/A |
| Average True Range (ATR) | 0.83 | 8.36 |
| MACD | 0.04 | -0.56 |
| Stochastic Oscillator | 70.89 | 71.08 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.